These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33116147)

  • 1. Genome editing of CCR5 by CRISPR-Cas9 in Mauritian cynomolgus macaque embryos.
    Schmidt JK; Strelchenko N; Park MA; Kim YH; Mean KD; Schotzko ML; Kang HJ; Golos TG; Slukvin II
    Sci Rep; 2020 Oct; 10(1):18457. PubMed ID: 33116147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
    Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of SIV-resistant T cells and macrophages from nonhuman primate induced pluripotent stem cells with edited CCR5 locus.
    D'Souza SS; Kumar A; Weinfurter J; Park MA; Maufort J; Tao L; Kang H; Dettle ST; Golos T; Thomson JA; Reynolds MR; Slukvin I
    Stem Cell Reports; 2022 Apr; 17(4):953-963. PubMed ID: 35364011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole genome sequencing of
    Schmidt JK; Kim YH; Strelchenko N; Gierczic SR; Pavelec D; Golos TG; Slukvin II
    Front Genome Ed; 2022; 4():1031275. PubMed ID: 36714391
    [No Abstract]   [Full Text] [Related]  

  • 5. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
    Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
    Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
    Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
    Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing.
    Kang X; He W; Huang Y; Yu Q; Chen Y; Gao X; Sun X; Fan Y
    J Assist Reprod Genet; 2016 May; 33(5):581-588. PubMed ID: 27052831
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Xu M
    Cell Biosci; 2020; 10():48. PubMed ID: 32257106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of concentration of CRISPR/Cas9 components on genetic mosaicism in cytoplasmic microinjected porcine embryos.
    Tanihara F; Hirata M; Nguyen NT; LE QA; Hirano T; Otoi T
    J Reprod Dev; 2019 Jun; 65(3):209-214. PubMed ID: 30726783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient generation of Knock-in/Knock-out marmoset embryo via CRISPR/Cas9 gene editing.
    Kumita W; Sato K; Suzuki Y; Kurotaki Y; Harada T; Zhou Y; Kishi N; Sato K; Aiba A; Sakakibara Y; Feng G; Okano H; Sasaki E
    Sci Rep; 2019 Sep; 9(1):12719. PubMed ID: 31481684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biallelic, Selectable, Knock-in Targeting of CCR5
    Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
    Front Immunol; 2022; 13():821190. PubMed ID: 35386712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Efficiency for Biallelic Mutations of the
    Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
    CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of mutation rates, mosaicism and off target mutations when injecting Cas9 mRNA or protein for genome editing of bovine embryos.
    Hennig SL; Owen JR; Lin JC; Young AE; Ross PJ; Van Eenennaam AL; Murray JD
    Sci Rep; 2020 Dec; 10(1):22309. PubMed ID: 33339870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 genome editing to create nonhuman primate models for studying stem cell therapies for HIV infection.
    Schmidt JK; Reynolds MR; Golos TG; Slukvin II
    Retrovirology; 2022 Aug; 19(1):17. PubMed ID: 35948929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental competence of porcine genome-edited zygotes.
    Gil MA; Martinez CA; Nohalez A; Parrilla I; Roca J; Wu J; Ross PJ; Cuello C; Izpisua JC; Martinez EA
    Mol Reprod Dev; 2017 Sep; 84(9):814-821. PubMed ID: 28471514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off- and on-target effects of genome editing in mouse embryos.
    Ayabe S; Nakashima K; Yoshiki A
    J Reprod Dev; 2019 Feb; 65(1):1-5. PubMed ID: 30518723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
    Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
    Cell Biosci; 2017; 7():47. PubMed ID: 28904745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
    Khan A; Paneerselvam N; Lawson BR
    Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient SSA-mediated precise genome editing using CRISPR/Cas9.
    Li X; Bai Y; Cheng X; Kalds PGT; Sun B; Wu Y; Lv H; Xu K; Zhang Z
    FEBS J; 2018 Sep; 285(18):3362-3375. PubMed ID: 30085411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of off-targeting in genome edited pigs produced via direct injection of the CRISPR/Cas9 system into developing embryos.
    Carey K; Ryu J; Uh K; Lengi AJ; Clark-Deener S; Corl BA; Lee K
    BMC Biotechnol; 2019 May; 19(1):25. PubMed ID: 31060546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.